Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Entrada Therapeutics, Inc. (NASDAQ: TRDA)
TRDA Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-14.60%
Analyst Rating:
BUY
Analyst Forecast (1yr):
215.30%
TRDA Stock Analysis
TRDA
PE Ratio:
TRDA
PEG Ratio:
Not Available
TRDA
Forward EPS Growth (12 month):
0.00%
TRDA
PS Ratio:
44.5
TRDA
PSG Ratio:
Not Available
TRDA
Forward Revenue Growth (12 month):
0.00%
TRDA Articles
No data was found